Answers are grounded in this paper and cite their sources.
Epigenetic nanorobots are an emerging concept at the intersection of epigenome editing, nanoscale delivery, sensing, and actuation. This review critically examines the rationale for reversible gene-state regulation, the technologies that may contribute to such systems, and the biological and engineering barriers to their integration. We distinguish experimentally demonstrated nanocarrier and nanorobotic functions from proposed capabilities, with particular attention to operational definitions, payload-specific delivery requirements, temporal reversibility, off-target effects, and translational feasibility. Current evidence supports several component technologies, including programmable epigenome editors, stimulus-responsive delivery systems, DNA nanostructures, and externally actuated micro/nanorobots; however, a unified epigenetic nanorobot capable of autonomous, closed-loop gene-state control has not yet been established clinically. We therefore present an evidence-based framework for evaluating this prospective field rather than claiming a validated therapeutic platform.
No takes yet. Share an insight, caveat, or question.
Antal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: